TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Modafinil in Treating Fatigue in Patients Receiving Chemotherapy for Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of cancer~* Concurrently receiving or has previously received chemotherapy and is scheduled for at least 3 additional courses of chemotherapy~  * Each course of chemotherapy must be at least 2 weeks in duration~ * No concurrent radiotherapy or interferon therapy~* Brief Fatigue Inventory question #3 fatigue worst score of 2 or greater 1 week after first chemotherapy course~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* Not specified~Life expectancy~* At least 6 months~Hematopoietic~* Not specified~Hepatic~* No uncontrolled anemia~Renal~* Not specified~Cardiovascular~* No history of clinically significant cardiac disease, including any of the following:~  * Unstable angina~ * Left ventricular hypertrophy~ * Ischemic echocardiogram changes~ * Chest pain~ * Arrhythmia~ * Other clinically significant manifestations of mitral valve prolapse in association with use of central nervous system stimulants (e.g., caffeine, amphetamines, or methylphenidate)~* No uncontrolled hypertension~Gastrointestinal~* Able to swallow medication~* No narrowing (pathological or iatrogenic) or obstruction of the gastrointestinal tract~Other~* No severe headaches~* No glaucoma~* No seizure disorder~* No narcolepsy~* No psychotic disorder~* No Tourette's syndrome~* No alcohol or drug abuse~* Not pregnant or nursing~* Fertile patients must use effective barrier contraception during and for at least 1 full menstrual cycle after study completion~PRIOR CONCURRENT THERAPY:~Biologic therapy~* See Disease Characteristics~Chemotherapy~* See Disease Characteristics~Endocrine therapy~* No concurrent chronic corticosteroids~Radiotherapy~* See Disease Characteristics~Surgery~* Not specified~Other~* No prior modafinil~* At least 30 days since prior regular use of psychostimulants (e.g., amphetamines, methylphenidate, or pemoline) or monoamine oxidase inhibitors (MAOIs)~* No concurrent alcohol~* Concurrent acetaminophen with codeine or hydrocodone bitartrate allowed~* Concurrent phenytoin allowed~* Concurrent warfarin for anticoagulation and low-dose warfarin (1 mg by mouth daily) for maintenance of venous access devices allowed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open Label Study Of SU011248 In Combination With Trastuzumab For Patients With Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* A diagnosis of breast cancer with evidence of 1) unresectable, locally recurrent, or 2) metastatic disease.~* HER2 positive disease (3+ by immunohistochemistry \[IHC\] or FISH-positive)~* Candidate for treatment with trastuzumab. Prior treatment with trastuzumab and or/ lapatinib in the neoadjuvant, adjuvant or metastatic disease setting is permitted. Treatment with hormone therapy in the adjuvant and/or advanced disease setting is permitted.~Exclusion Criteria:~* Prior treatment with \>1 regimen of cytotoxic therapy in the advanced disease setting. Adjuvant chemotherapy is permitted~* Prior exposure to trastuzumab if the patient had developed severe hypersensitivity reactions.~* Prior treatment on a SU11248 clinical trial.~* Uncontrolled brain metastases.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cervical or Vaginal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically confirmed advanced, persistent, or recurrent clear cell adenocarcinoma of the vagina or cervix Documented disease progression after local therapy required Disease must be considered incurable Bidimensionally measurable disease required by physical examination or medical imaging~PATIENT CHARACTERISTICS: Age: Any age Performance status: GOG 0-2 Hematopoietic: WBC at least 3,000 AGC at least 1,500 Platelets at least 100,000 Hepatic: Bilirubin no more than 1.5 times normal AST no more than 3 times normal Alkaline phosphatase no more than 3 times normal Renal: Creatinine no more than 2.0 mg/dL Other: Not eligible for a higher priority GOG protocol No significant infection No prior or concomitant second malignancy except nonmelanomatous skin cancer~PRIOR CONCURRENT THERAPY: At least 3 weeks since therapy directed at malignancy Biologic therapy: Not specified Chemotherapy: No more than 1 prior chemotherapy regimen (either single or combination cytotoxic drug therapy) No prior paclitaxel Recovery from prior chemotherapy required Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy for recurrent disease except a low dose, single fraction used to abrogate menorrhagia Recovery from prior radiotherapy required Surgery: Recovery from prior surgery required

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Actovegin in Post-stroke Cognitive Impairment (PSCI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Main Inclusion Criteria:~* Participant has suffered a recent supra-tentorial ischaemic stroke supported by computed tomography (CT) scan or magnetic resonance imaging (MRI) findings (in accordance with local practice).~* Participant is male or female, aged 60 years or above.~* Participant has a score on the National Institute of Health Stroke Scale (NIHSS) between 3 and 18 (inclusive).~* Participant is capable of completing the Montreal Cognitive Assessment (MoCA) and has a score of ≤ 25 points with adjustment for level of education (4-9 school years ≤ 23 points, 10-12 years ≤ 24 points, \>12 years ≤ 25 points).~Main Exclusion Criteria:~* Participant has a medical history of dementia.~* Participant has a known medical history of major depression or psychotic disorder.~* Participant is indicated for treatment with thrombolytics or carotid surgery as the current standard of care.~Randomisation Criteria:~* Inclusion Criteria.~* Ability to perform Alzheimer's Disease Assessment Scale + Cognitive Subscale Extended Version (ADAS-cog+).~* Exclusion Criteria.~* Clinically there is suspicion of progressive stroke.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Actovegin (Type: ACTIVE_COMPARATOR): Actovegin 2000 mg solution, intravenous (IV) infusion for up to 20 days followed by 2 actovegin 200 mg, tablets, orally, 3 times a day for up to 6 months.
- Placebo (Type: PLACEBO_COMPARATOR): Actovegin placebo-matching solution, intravenous (IV) infusion for up to 20 days followed by 2 actovegin placebo-matching, tablets, orally, 3 times a day for up to 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose-varied Evaluation of Ablavar-enhanced MR Angiography of the Central Veins of the Chest in Healthy Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* healthy male or female subjects between 18-45 years of age~Exclusion Criteria:~* Pregnant and lactating females~* known renal impairment~* allergy to gadolinium-based contrast~* metallic implanted devices~* claustrophobia.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- 0.03 mmol/kg (Type: ACTIVE_COMPARATOR): FDA-approved dose for lower extremity arterial imaging
- 0.02 mmol/kg (Type: EXPERIMENTAL): None
- 0.01 mmol/kg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cetuximab and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed non-small cell lung cancer (NSCLC)~  * Stage IIIA or IIIB disease~* Must be a candidate for curative radiotherapy~* Not a candidate for other concurrent chemotherapy and radiotherapy~* No surgical treatment available~* No pleural effusion suspected or proven to be malignant~* No stage IV disease by bone scan or positron emission tomography scan, CT scan or MRI of the brain, and CT scan of the chest within the past 30 days~PATIENT CHARACTERISTICS:~Age \* 18 and over~Performance status~* Eastern Cooperative Oncology Group (ECOG) 0-2 (age ≥ 65 years)~* ECOG 2 (age 18 to 64 years)~Life expectancy~\* At least 12 weeks~Hematopoietic~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Hemoglobin ≥ 9 g/dL~Hepatic~* Bilirubin ≤ 2 times upper limit of normal (ULN)~* AST ≤ 3 times ULN~Renal~* Creatinine ≤ 1.5 times ULN~Pulmonary~* FEV_1 ≥ 1 L~* No idiopathic pulmonary fibrosis~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* Magnesium normal~* No uncontrolled infection~* No other severe underlying disease that would preclude study entry~* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or noninvasive carcinoma~* No major psychiatric illness that would preclude study participation~PRIOR CONCURRENT THERAPY:~Biologic therapy~\* Not specified~Chemotherapy~* See Disease Characteristics~* No prior chemotherapy for NSCLC~Endocrine therapy~\* Not specified~Radiotherapy~* No prior therapeutic radiotherapy to the chest~* No concurrent intensity modulated radiotherapy~Other~\* No prior epidermal growth factor receptor inhibitors

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- cetuximab/Radiation (Type: EXPERIMENTAL): Cetuximab (C225) and Radiation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Effect of Ivacaftor on Lung Clearance Index in Subjects With Cystic Fibrosis and the G551D Mutation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects with confirmed diagnosis of CF~* Must have the G551D-CFTR mutation in at least 1 allele~* FEV1 \>90% of predicted normal for age, gender, and height~Exclusion Criteria:~* Ongoing participation in another therapeutic clinical study or prior participation in an investigational drug study within the 30 days prior to screening~* Use of inhaled hypertonic saline treatment within 2 weeks of the Period 1, Day 1 visit

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Sequence 1 (Type: EXPERIMENTAL): Ivacaftor administered in Treatment Period 1 and placebo administered in Treatment Period 2.
- Treatment Sequence 2 (Type: EXPERIMENTAL): Placebo administered in Treatment Period 1 and ivacaftor administered in Treatment Sequence 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Replacement of Lamivudine by Telbivudine to Improve Renal Function

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Sign inform consent~2. Age is not less than 16 years old.~3. Post liver transplantation patient for HBV-related indication.~4. Chronic hepatitis B transplant patients who are treated by lamivudine for not less than 6 months.~5. eGRF stage 2-4 patients (15\<eGFR\<90ml)~6. Stable liver function, ALT not more than 2 folds of upper limit.~Exclusion Criteria:~1. Acute rejection with increase CNI dose within a month.~2. Pregnant or nursing.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Lamivudine group (Type: NO_INTERVENTION): continue Lamivudine
- Telbivudine group (Type: EXPERIMENTAL): Telbivudine replaces Lamivudine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients, age 18 years or older~* Philadelphia chromosome (Ph) positive chronic myelogenous leukemia in either chronic, accelerated, or blast phase~* The patient will have the T315I BCR-ABL gene mutation~* Patients will have failed prior imatinib therapy~* ECOG performance status 0-2~Exclusion Criteria:~* NYHA class III or IV heart disease, active ischemia or any other uncontrolled cardiac condition such as angina pectoris, clinically significant cardiac arrhythmia and requiring therapy, uncontrolled hypertension or congestive heart failure~* Myocardial infarction in the previous 12 weeks~* Lymphoid Ph+ blast crisis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- omacetaxine (Type: EXPERIMENTAL): Treatment was the same for all cohorts: induction therapy was subcutaneous (SC) administration of omacetaxine at 1.25 mg/m\^2 twice a day (BID), administered for 14 consecutive days every 28 (±3) days for up to 6 cycles. Maintenance therapy was subcutaneous (SC) administration of omacetaxine at 1.25 mg/m\^2 twice a day (BID), administered for 7 consecutive days every 28 (±3) days for up to 3 years.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Postoperative Tolvaptan Use in Left Ventricular Assist Device Implantation Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Hospitalized patients with American College of Cardiology (ACC) and the American Heart Association (AHA) Stage D heart failure and plan to undergo LVAD implantation~* Age greater than or equal to 18 years old~Exclusion Criteria:~* No plan for LVAD implantation~* Age less than 18 years old

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- tolvaptan (TLV) (Type: None): LVAD recipients with post-operative hyponatremia (Na \< 135 mEq/L). Eligible patients took tolvaptan 15 mg daily as part of a routine care treatment plan.
- no tolvapton (no-TLV) (Type: None): LVAD recipients with post-operative hyponatremia (Na \< 135 mEq/L). Eligible patients did not take tolvaptan as part of routine care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Initiating Tiotropium Alone Versus Initiating Tiotropium in Combination With Fluticasone Propionate/Salmeterol Xinafoate Combination (FSC) on Chronic Obstructive Pulmonary Disease-related Outcomes in Patients With Pre-existing Exacerbations

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Continuous health plan eligibility in the pre- and post-index periods~* age ≥40 years at the index date~* Presence of at least 1 claim with an ICD-9-CM code for COPD in any diagnosis field (490.xx, 491.xx, 492.xx, 496.xx) in the pre- and post-index period~* ≥1 exacerbation in the pre-index period (defined as a COPD-related Emergency Room visit or hospitalization)~* ≥1 prescription claim for ipratropium or ipratropium/albuterol combination in the pre-index period~* an index event of at least one pharmacy claim for TIO (tiotropium) combination in the pre-index period during the study period (January 1, 2003 through April 30, 2008)~* ≥2 prescriptions for TIO (including the index prescription) during the post-index period~Exclusion Criteria:~* presence of comorbid conditions (respiratory cancer, cystic fibrosis, fibrosis due to tuberculosis \[TB\], and bronchiectasis, pneumonociosis, pulmonary fibrosis, pulmonary TB, sarcoidosis) during the pre- and post-index periods~* use of FSC in pre-index period~* exacerbation (emergency room visit or hospitalization) within 30 days after the index date

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- COPD patients (Type: None): Patients who are at least 40 years of age and diagnosed with COPD using ICD-9 codes of 491.xx, 492.xx, and 496.xx in an administrative claims database.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Preferred Treatment of Type 1.5 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age at onset of diabetes - 35-69 years old.~* No history of ketonuria or ketoacidosis.~* Not requiring insulin to achieve glycemic control.~* Not receiving more than two oral hypoglycemic agents.~* Not taking a thiazolidinedione agent.~* HbA1c in established patients (on an oral hypoglycemia agent for over 4 months) of greater than 6% and under 10%.~* Fasting c-peptide greater than or equal to 0.8 ng/ml.~* Women must be either post-menopausal or on adequate birth control (i.e. oral contraceptives, tubal ligation, hysterectomy, condoms, or diaphragm) or use abstinence.~Exclusion Criteria:~* Patients with history of chronic pancreatitis or other secondary causes of diabetes.~* Patients receiving systemic corticosteroids.~* Patients with severe systemic illness (e.g. recent MI, CHF or cerebral vascular disease).~* Creatinine greater than 1.4 or liver enzymes greater than 2 times the upper limits of normal.~* Not able to adhere to the protocol.

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- rosiglitazone (Type: ACTIVE_COMPARATOR): Rosiglitazone is an oral antidiabetic agent which acts primarily by increasing insulin sensitivity. The rosiglitazone treatment group commenced therapy with 4 mg once per day and increase to twice per day if adequate glycemic control was not achieved.
- glyburide (Type: ACTIVE_COMPARATOR): Glyburide is a sulfonylurea. Glyburide therapy was initiated with 2.5 mg in the morning or the patient was maintained on the dose they had been receiving prior to starting the study. This starting dose was raised by 2.5 in the evening and further up to a maximum of 10 mg twice a day if necessary to achieve desired glycemic control.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete